INVA - NASDAQ

Innoviva, Inc.

INVA·NASDAQ

$21.70

+0.88%

HealthcareBiotechnology

Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.60B

EPS4.0200

P/E Ratio5.40

Earnings Date08/05/2026

1.64B

Assets

26%

3Y+33.0%

5Y+64.0%

10Y+331.0%

462.32M

Total Liabilities

-24%

3Y-31.0%

5Y+18.0%

10Y-37.0%

1.17B

Total Equity

70%

3Y+107.0%

5Y+93.0%

10Y-432.0%

Innoviva, Inc. Funding & Solvency Profile

INVA · NASDAQ

Current Assets

Cash & Cash Equivalents550.94M

Net Receivables34.97M

Inventory39.17M

Other Current Assets102.44M

Total Current Assets728 M

Non-Current Assets

Property, Plant & Equipment12.48M

Goodwill & Intangible Assets200.06M

Long-Term Investments193.73M

Other Non-Current Assets501.38M

Total Non-Current Assets708 M

Total Assets

1.64B

Financial Health Analysis

Current Ratio

14.64x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.39x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

678 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

44% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Innoviva, Inc. Balance Sheet

INVA • NASDAQ

Innoviva, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008	Dec 2007	Dec 2006
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	550.9M	305M	193.5M	291M	201.5M	246.5M	278.1M	62.4M	73.3M	118M	159.2M	96.8M	143.5M	94.8M	44.8M	163.3M	47.5M	92.3M	86.4M	72.4M
Short-Term Investments	0.0	107.5M	0.0	0.0	0.0	0.0	72.7M	52.5M	55.7M	32.4M	28.1M	143.7M	321.6M	153.6M	196.1M	146.3M	107.8M	108.3M	40.4M	128.7M
Cash & Short-Term Investments	550.9M	412.5M	193.5M	291M	201.5M	246.5M	350.8M	114.9M	129.1M	150.4M	187.3M	240.5M	465.1M	248.5M	240.9M	309.6M	155.4M	200.6M	126.8M	201.1M
Net Receivables	35M	86.4M	84.1M	64.1M	110.7M	93.9M	79.4M	83.3M	70.5M	46.8M	26.2M	10.6M	3.4M	1.1M	323K	194K	418K	553K	539K	608K
Accounts Receivables	35M	20.4M	14.5M	9.4M	110.7M	93.9M	79.4M	83.3M	70.5M	46.8M	26.2M	10.6M	3.4M	1.1M	223K	194K	144K	287K	316K	608K
Other Receivables	0.0	66M	69.6M	54.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	274K	0.0	0.0	0.0
Inventory	39.2M	33.7M	40.7M	55.9M	0.0	0.0	0.0	-83.3M	-754K	-46.8M	-26.2M	0.0	10.4M	7.5M	0.0	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	21.1M	21.6M	29.6M	1.4M	1.6M	962K	849K	754K	766K	814K	1.1M	4.3M	4.1M	3.5M	6M	6.2M	8.8M	6.7M	4.4M
Other Current Assets	102.4M	656K	4.3M	2.9M	70K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Current Assets	727.5M	554.3M	344.2M	443.5M	313.7M	342.1M	431.2M	199M	199.6M	198M	214.3M	252.2M	483.2M	261.1M	244.8M	316.4M	162M	210M	134.1M	207.2M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	12.5M	3M	3M	3.4M	109K	28K	33K	160K	209K	368K	221K	324K	10.2M	9.2M	10.4M	10.2M	12.9M	16.2M	20.1M	15.1M
Goodwill	17.9M	17.9M	17.9M	26.7M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	182.2M	208.4M	230.3M	252.9M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	324K	124.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	200.1M	226.3M	248.2M	279.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	324K	124.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	193.7M	394M	561M	403M	483.8M	438.3M	0.0	0.0	0.0	0.0	0.0	42.9M	55.4M	95.2M	0.0	0.0	0.0	0.0	2M	34M
Tax Assets	0.0	12.1M	0.0	0.0	0.0	93.8M	154.2M	196.1M	0.0	0.0	0.0	-324K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	501.4M	111.4M	87.1M	101.9M	128.8M	125.5M	139.4M	152.9M	167.5M	180.6M	209.5M	226.3M	8.2M	3.1M	3.6M	4.6M	6.4M	10M	5.8M	6.2M
Total Non-Current Assets	907.7M	746.8M	899.3M	788M	612.7M	657.5M	293.6M	349.2M	167.7M	181M	209.7M	269.5M	198.1M	107.4M	14M	14.8M	19.4M	26.2M	27.9M	55.3M
Total Assets	1.6B	1.3B	1.2B	1.2B	926.4M	999.6M	724.8M	548.2M	367.3M	379M	424.1M	521.7M	681.3M	368.6M	258.8M	331.2M	181.4M	236.2M	162M	262.4M
LIABILITIES
CURRENT LIABILITIES
Total Payables	5M	5.1M	6.7M	3.1M	27K	66K	10K	11K	601K	128K	818K	1.1M	7.6M	5.4M	5.8M	2.1M	1.8M	3.3M	7M	16M
Accounts Payable	5M	2.1M	6.7M	2.9M	27K	66K	10K	11K	601K	128K	818K	0.0	7.6M	5.4M	5.8M	2.1M	1.8M	3.3M	7M	16M
Other Payables	0.0	3M	0.0	154K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	29.8M	28.9M	29.6M	5.7M	6M	647K	470K	9.1M	11.3M	11.8M	2M	10.9M	9M	9.6M	7.2M	6.3M	8.9M	11.8M	8.3M
Short Term Debt	418K	192M	0.0	96.2M	0.0	0.0	0.0	0.0	25M	7.8M	0.0	0.0	0.0	0.0	69K	206K	184K	117K	101K	87K
Capital Lease Obligations (Current)	0.0	1.6M	1.2M	1.3M	106K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	274K	53.2M	11.8M	154K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	4.3M	1.1M	1.3M	2.1M	0.0	0.0	0.0	0.0	-19.7M	885K	885K	1.1M	9.3M	4.6M	18.7M	21.9M	23.7M	23.8M	22.5M	19.3M
Other Current Liabilities	40M	6.4M	0.0	2.6M	0.0	0.0	4.7M	5.2M	0.0	0.0	0.0	9.7M	56.7M	11M	11.3M	8.6M	6.9M	7.8M	14.1M	15.9M
Total Current Liabilities	49.7M	236.1M	38.1M	135M	5.8M	6.1M	5.4M	5.7M	9.7M	11.4M	12.6M	13.8M	84.4M	30M	45.5M	40.1M	38.9M	44M	55.5M	59.6M
NON-CURRENT LIABILITIES
Long Term Debt	257.7M	256.3M	446.2M	444.2M	394.7M	385.5M	377.1M	382.9M	574.4M	708.3M	733.1M	725.6M	287.5M	172.5M	172.5M	172.6M	172.8M	172.8M	435K	538K
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1M	4M	3.8M	5.5M	6M	122M	137.4M	158.3M	152.8M	166.1M	134.4M
Deferred Tax Liabilities (Non-Current)	31.8M	0.0	563K	5.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	105K	-276.1M	-168.5M	-269.9M	-285.7M	0.0	-152.8M	-166.1M	-134.4M
Other Non-Current Liabilities	112.2M	116.3M	82M	78.4M	0.0	106K	219K	586K	940K	1.4M	1.9M	1.8M	4.8M	5.1M	5.8M	3.6M	389K	0.0	4.1M	4.6M
Total Non-Current Liabilities	412.6M	373.8M	530.4M	530.7M	394.7M	385.6M	377.3M	383.4M	600.3M	720.6M	754.1M	731.2M	297.7M	183.6M	300.3M	313.6M	331.4M	327.2M	172.7M	139.5M
Capital Lease Obligations	10.9M	2.8M	2.8M	3.7M	106K	0.0	100K	500K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	462.3M	609.9M	568.6M	665.7M	400.5M	391.7M	382.7M	389.1M	610M	732M	766.7M	745M	382.1M	213.6M	345.8M	353.6M	370.4M	371.1M	228.2M	199.1M
SHAREHOLDERS' EQUITY
Treasury Stock	0.0	0.0	-393.8M	-393.8M	-393.8M	0.0	0.0	0.0	-3.3M	-3.3M	-3.3M	-3.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common Stock	747K	627K	633K	692K	696K	1M	1M	1M	1M	1.1M	1.1M	1.2M	1.1M	984K	855K	804K	643K	619K	610K	601K
Additional Paid-In Capital	902.7M	692.3M	1.1B	1.2B	1.3B	1.3B	1.3B	1.3B	1.3B	1.3B	1.4B	1.5B	1.8B	1.5B	1.2B	1.2B	927.1M	895.4M	870.9M	840.5M
Retained Earnings	269.4M	-1.8M	-25.2M	-204.9M	-456.1M	-722M	-946.4M	-1.1B	-1.5B	-1.6B	-1.7B	-1.7B	-1.5B	-1.3B	-1.3B	-1.2B	-1.1B	-1B	-937.8M	-777.8M
Accumulated Other Comprehensive Income/Loss	0.0	0.0	0.0	0.0	0.0	0.0	27K	-3K	-18K	1K	-2K	-87K	162K	99K	16K	33K	35K	501K	57K	23K
Total Stockholders' Equity	1.2B	691.2M	675M	565.8M	414.7M	539.9M	313.5M	153.6M	-242.9M	-353M	-342.6M	-223.3M	299.1M	155M	-87.1M	-22.4M	-189M	-134.9M	-66.3M	63.3M
Total Equity	1.2B	691.2M	675M	565.8M	525.9M	607.8M	342.1M	159.1M	-242.7M	-353M	-342.6M	-223.3M	299.1M	155M	-87.1M	-22.4M	-189M	-134.9M	-66.3M	63.3M
Minority Interest	0.0	0.0	0.0	0.0	111.2M	67.9M	28.6M	5.5M	152K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SUMMARY
Total Liabilities & Equity	1.6B	1.3B	1.2B	1.2B	926.4M	999.6M	724.8M	548.2M	367.3M	379M	424.1M	521.7M	681.3M	368.6M	258.8M	331.2M	181.4M	236.2M	162M	262.4M
Total Investments	193.7M	501.5M	561M	403M	483.8M	438.3M	72.7M	52.5M	55.7M	32.4M	28.1M	186.6M	377M	248.8M	196.1M	146.3M	107.8M	108.3M	42.4M	162.7M
Total Debt	269M	451.1M	449.1M	544.1M	394.8M	385.5M	377.1M	382.9M	599.4M	716.1M	748.3M	725.6M	287.5M	172.5M	172.6M	172.8M	173M	172.9M	536K	625K
Net Debt	-281.9M	146.1M	255.6M	253M	193.2M	139M	99M	320.4M	526M	598.1M	589.1M	628.8M	144M	77.7M	127.8M	9.4M	125.4M	80.7M	-85.9M	-71.8M
Shares Outstanding	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319	64,335,319

SEC Filings

INVA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 18, 2026	May 12, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 06, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 06, 2026	May 06, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 04, 2026	May 04, 2026	2026	View Filing
10-K/A 10-K/A 2025 FY (Amended) FY	March 27, 2026	December 31, 2025	2025	View Filing
DEF 14A DEF 14A 2026 N/A	March 24, 2026	March 24, 2026	2026	View Filing
8-K 8-K 2026 N/A	February 25, 2026	February 25, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 25, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2025 N/A	November 05, 2025	November 05, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 05, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 549 filings

Related Guides

Blog Categories

Continue your INVA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.